{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:31:25Z","timestamp":1783654285359,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Thoracic SMARCA4-deficient undifferentiated tumor (T-SMARCA4-DUT) is a rare neoplastic entity with a high risk of being misdiagnosed. We report the case of a 64-year-old male initially suspected of having mediastinal lymphoma by contrast-enhanced chest computed tomography (CECCT), and pathologically diagnosed with metastatic poorly differentiated lung adenocarcinoma via cervical lymph node biopsy. Initial immunohistochemical (IHC) results showed TTF-1 (clone SPT24) (+), Napsin A (-), p40 (-), and next-generation sequencing (NGS) detected KRAS amplification and TP53 missense mutation. Combined chemotherapy plus immunotherapy initially shrank the tumor, but bilateral axillary lymphadenopathy subsequently developed. Pathological analysis of axillary metastases and supplementary IHC of the original cervical biopsy revealed SMARCA4\/Brg1 (-), SOX2 (+) and TTF-1 (clone 8G7G3\/1) (-), leading to a revised diagnosis of lymph node-metastatic T-SMARCA4-DUT. This case identifies the non-specific clinical features of T-SMARCA4-DUT and an inadequate initial IHC panel as the core causes for misdiagnosis and confirms that a definitive diagnosis requires testing for SMARCA4\/Brg1, SOX2, and the highly specific TTF-1 (clone 8G7G3\/1).<\/jats:p>","DOI":"10.3389\/fonc.2026.1813580","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:46:24Z","timestamp":1776059184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Thoracic SMARCA4-deficient undifferentiated tumor prone to misdiagnosis as lung adenocarcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiuwen","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, The First People\u2019s Hospital of Xiaoshan District","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First People\u2019s Hospital of Xiaoshan District","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The First People\u2019s Hospital of Xiaoshan District","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First People\u2019s Hospital of Xiaoshan District","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First People\u2019s Hospital of Xiaoshan District","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic Malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer","year":"2015","journal-title":"Nat Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf121","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor: Diagnostic characteristics, molecular insights, and treatment approaches","volume":"30","author":"Song","year":"2025","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/his.15063","article-title":"NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumour: Facts and controversies","volume":"84","author":"Yoshida","year":"2024","journal-title":"Histopathology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-541","article-title":"SMARCA4-deficient undifferentiated thoracic tumor: A case report and literature review","volume":"17","author":"Liu","year":"2025","journal-title":"J Thorac Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad175","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor: Current knowledge and future perspectives","volume":"54","author":"Shinno","year":"2024","journal-title":"JPN J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12672-023-00639-w","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor","volume":"14","author":"Jiang","year":"2023","journal-title":"Discov Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00292-019-0589-0","article-title":"Immunph\u00e4notypisierung von Lungentumoren: Ein Update [Immunophenotyping of lung tumors: An update","volume":"40","author":"Warth","year":"2019","journal-title":"Pathologe"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.05.011","article-title":"Innocuous clinical presentation of a SMARCA4-deficient thoracic sarcoma arising in a patient with chronic empyema thoracis","volume":"51","author":"Nambirajan","year":"2019","journal-title":"Pathology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.024","article-title":"SMARCA4 and other SWItch\/Sucrose NonFermentable family genomic alterations in NSCLC: Clinicopathologic characteristics and outcomes to immune checkpoint inhibition","volume":"16","author":"Alessi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111102","article-title":"Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management","volume":"11","author":"\u0160uti\u0107","year":"2021","journal-title":"J Pers Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biom11111721","article-title":"Real-world diagnostic accuracy and use of immunohistochemical markers in lung cancer diagnostics","volume":"11","author":"Ericson Lindquist","year":"2021","journal-title":"Biomolecules"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9118","DOI":"10.1200\/JCO.2023.41.16_suppl.9118","article-title":"Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer","volume":"41","author":"Ricciuti","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104554","article-title":"KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies","volume":"205","author":"Liguori","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1186\/s12885-022-10246-7","article-title":"Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: Associations with environmental factors and clinical outcomes","volume":"22","author":"Sato","year":"2022","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-927","article-title":"Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients","volume":"10","author":"Fung","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.31557\/APJCP.2025.26.1.17","article-title":"Prognosis of TP53 and its concomitant EGFR mutation in lung cancer especially non-small cell lung cancer","volume":"26","author":"Mehta","year":"2025","journal-title":"Asian Pac J Cancer Prev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/modpathol.2017.11","article-title":"Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities","volume":"30","author":"Yoshida","year":"2017","journal-title":"Mod Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1813580\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:46:25Z","timestamp":1776059185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1813580\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":19,"alternative-id":["10.3389\/fonc.2026.1813580"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1813580","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1813580"}}